BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 30, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» CAV3 as therapeutic target for mitochondrial dysfunction in diabetic cardiomyopathy
To read the full story,
subscribe
or
sign in
.
Cardiovascular
CAV3 as therapeutic target for mitochondrial dysfunction in diabetic cardiomyopathy
May 8, 2024
No Comments
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
BioWorld Science
Cardiovascular
Endocrine/metabolic